“At Pfizer, we are committed to developing breakthroughs that change patients' lives,” said Anne Harris, the managing director of Pfizer Australia and New Zealand.
Pfizer's Velsipity PBS-listed for people with moderately to severely active ulcerative colitis
October 1, 2024 Latest NewsBioPharma
Latest Video
New Stories
-
The industry is probably right to resist, it just needs to prepare for the response
December 16, 2025 - - Latest News -
Cynata completes patient enrolment in Phase 2 trial for aGvHD therapy
December 15, 2025 - - Australian Biotech -
Prescient secures European approval to launch PTX-100 trial for rare lymphoma
December 15, 2025 - - Australian Biotech -
Orthocell lodges European and UK regulatory application for Remplir
December 15, 2025 - - Australian Biotech -
Neuren wins second FDA approval for trofinetide with launch of formulation
December 15, 2025 - - Australian Biotech -
Dimerix completes adult recruitment in Phase 3 trial for FSGS treatment DMX-200
December 15, 2025 - - Australian Biotech -
Radiopharm Theranostics reports high success rate in Phase 2b imaging trial
December 15, 2025 - - Australian Biotech
